Anti-human annexin A1 antibody

摘要

The present invention relates to isolated specific binding molecules that bind to human Anx-A1 and include VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2, and VHCDR3 as complementarity determining regions (CDRs), wherein each of the CDRs comprises: Has the amino acid sequence of That is, VLCDR1 has the sequence shown in SEQ ID NO: 1, SEQ ID NO: 36 or SEQ ID NO: 37, VLCDR2 has the sequence shown in SEQ ID NO: 2, VLCDR3 has the sequence shown in SEQ ID NO: 3, and VHCDR1 Has the sequence shown in SEQ ID NO: 4, VHCDR2 has the sequence shown in SEQ ID NO: 5, and VHCDR3 has the sequence shown in SEQ ID NO: 6, or in each sequence, the sequence identity to that sequence Is an amino acid sequence that is at least 85%. The disclosed specific binding molecules are therapeutically useful, especially T cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD related diseases), and anxiety disorders. It can be used in the treatment of OCD-related diseases. [Selection diagram] None